Theralase Anti-Cancer Drugs Appear in Peer-Reviewed Study

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced their lead anti-cancer drug TLD-1433 has been verified as part of a peer-reviewed publication.
As quoted in the press release:

A detailed computational investigation (“Study”) by Marta Alberto and co-workers entitled, “Theoretical Exploration of Type I/Type II Dual Photoreactivity of Promising Ru(II) Dyads for PDT Approach,” appearing in the peer-reviewed American Chemical Society (“ACS”) journal Inorganic Chemistry, has independently verified and validated the unique photo-physical properties of Theralase’s lead Photo Dynamic Compound (“PDC”), TLD-1433, and associated family of compounds.
The Study details how Dr. Sherri McFarland (“McFarland”), Professor, Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro, has pioneered the use of specialized excited states for dual-mode Type I (oxygen independent) / II (oxygen dependent) photo-reactivity as a means of creating novel classes of PDCs with potencies that are orders of magnitude greater than those of traditional photo-sensitizers used for Photo Dynamic Therapy (“PDT”).

Click here to read the full press release.

Source: www.accesswire.com